BACKGROUND: Pulmonary nodules (PNs) are a common reason for referral to pulmonologists. Th e majority of data for the evaluation and management of PNs is derived from studies performed in academic medical centers. Little is known about the prevalence and diagnosis of PNs, the use of diagnostic testing, or the management of PNs by community pulmonologists.
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A pulmonary nodule (PN) is defi ned as a radiographic opacity Յ 3 cm in diameter surrounded by lung parenchyma. 1 Th e prevalence of PNs is unknown, with estimates ranging from 150,000 to 1 million per year in the United States. 2 Th e identifi cation of PNs may increase over the next decade for several reasons. First, chest CT scans are ordered frequently for a myriad of clinical indications, including dyspnea or chest pain. Smith-Bindman et al 3 estimate the rate of chest CT scanning as 23 per 1,000, which, extrapolated to the US population, equates to approximately 7 million chest CT scans performed annually. Second, the National Lung Screening Trial found three fewer deaths from lung cancer per 1,000 in those screened annually for 3 years with low-dose chest CT scans, leading to the B recommendation by the US Preventive Services Task Force 4 to screen high-risk individuals with yearly low-dose CT scans. However, the National Lung Screening Trial also found a 25% rate of screen-detected nodules, 96% of which were benign. Currently, 8.6 million Americans meet the criteria for screening. 5 Depending on the penetration of screening, the incidence of detected PNs could increase dramatically. 6 Th e American College of Chest Physicians (CHEST) and the Fleischner Society have published guidelines for management based on pretest probability of malignancy (pCA). 7, 8 Management decisions fall into three general categories based on the physician's pCA. For those in whom the pCA is low, serial imaging is recommended. When
Materials and Methods
Th is was a multicenter, community-based, retrospective observational study of patients with PNs, ranging from 8 to 20 mm in diameter, presenting to 18 geographically representative outpatient pulmonary clinics across the United States. Th e study was approved at 15 sites by a central institutional review board and at three sites by local institutional review board approval.
Site Selection
Four hundred forty sites were identifi ed based on investigator databases and claims data from a large insurance carrier whose coverage population was representative of the overall US population. Of these, 77 sites expressed interest in participating, and 48 sites went on to sign confidentiality agreements. Of these, 17 did not request additional information, leaving 31 sites undergoing qualifi cation review. Eighteen outpatient pulmonary clinics were chosen to participate based on the following criteria: (1) management of patients with PNs, (2) availability of medical records, and (3) ability to perform data abstraction. In addition, investigators targeted enrollment of geographically diverse patients to limit the potential bias associated with diff erences in practice patterns and to account for variation in disease prevalence (eg, endemic mycoses) that could alter management decisions.
Patient Selection
Patients were identifi ed by querying databases (eg, billing and scheduling systems) using fi ve International Classifi cation of Diseases , Ninth Revision , Clinical Modifi cation codes for PN (793.1, 786.6, 518.89, 519.8, 519.9) to ensure homogeneity in patient identifi cation and inclusion. 17 Manual chart abstraction was then used to identify those who met the criteria. To minimize selection bias, the sites were not permitted to use additional codes during database query to identify patients. To ensure a systematic sample, patient eligibility was determined by examining consecutively referred patients to the site.
Inclusion criteria included age Ն 40 years and Յ 89 years at the time of nodule fi nding, presentation to a pulmonologist, nodule size 8 to 20 mm, and definitive diagnosis ascertained by tissue diagnosis or radiographic follow-up for 2 years. Exclusion criteria included chest CT scan performed . 60 days prior to the initial visit, prior diagnosis of any cancer within 2 years of nodule detection, or incomplete chart data.
Patients were categorized into three groups by the most invasive procedure performed during management, as follows: surveillance (serial imaging), biopsy (CT scan-guided transthoracic needle aspiration [TTNA] or bronchoscopy), or surgery (including mediastinoscopy, video-assisted thorascopic surgery, and/or thoracotomy).
Data Collection
Clinical data were abstracted retrospectively by designated study staff into an electronic data capture system from initial consultation through establishment of a defi nitive diagnosis (ie, pathology results) or a minimum 2-year follow-up. Data included patient demographic and clinical characteristics, PN characteristics, imaging tests, invasive testing, and surgery. PET scan reports were reviewed and abstracted where available for a subset of patients. To adjudicate a PET scan the pCA is intermediate, functional imaging (PET scan), biopsy, or both is warranted. When the pCA is high, surgery is recommended. 8 Although these recommendations appear straightforward, other factors such as patient comorbidities and preferences oft en infl uence the choice of management strategy. 8 Clinical prediction models have been developed and validated to assess the pCA in PNs, which can be used to help guide decisions about selection and interpretation of additional diagnostic testing. [9] [10] [11] [12] Outside clinical practice guidelines, there remain significant challenges in interpretation of the literature. First, the prevalence of malignancy in a PN varies by the context within which it is studied, from a low of 2% in lung cancer screening trials to a high of 83% in surgical series. [13] [14] [15] Unfortunately, most of these studies are from single-center academic institutions focused on a single aspect of nodule management (eg, PET scan use) and do not always combine modalities to give a cohesive picture of how nodules are managed from presentation to fi nal outcome. We undertook this study to better understand the management patterns of physicians faced with the evaluation of intermediate-sized nodules, which most oft en present a diagnostic dilemma, 16 in community settings across the United States.
report as positive or negative, an algorithm was developed that prioritized the following components of the report from highest to lowest: fi nal radiology impression, description of fi ndings, and standard uptake values (SUVs) ( e- Fig 1 ) . PET scanning was defi ned as negative if the report included any of the following statements: no evidence of malignancy, no 18F-fl uorodeoxyglucose uptake or hypermetabolic activity, or an SUV of , 2.5. A positive PET scan was defi ned as a report that included any of the following statements: concern or suggestion of malignancy, fi ndings that described increased 18F-fl uorodeoxyglucose uptake or hypermetabolic activity, or an SUV Ն 2.5. In the 27 cases in which the fi ndings were discordant with the fi nal impression, adjudication was performed by two independent pulmonologists and agreement was reached in all cases. Data quality was ensured through ongoing site monitoring. Programmed edit checks were built into the electronic data capture system and at the conclusion of chart abstraction, each site provided access to a random 10% sample of deidentifi ed patient records for review.
Pretest Probability of Malignancy
Two previously developed and validated models 9,10 were used to estimate the pCA in each patient. Model accuracy was determined by comparing the pCA with the fi nal diagnosis. Receiver operating characteristic curves and the area under the curve were generated with 95% CIs. Th e pCA was calculated for each patient and categorized into three groups ( , 5%, 5% to , 65%, and Ն 65%). Procedure use by group was examined.
Data Analysis
x 2 or analysis of variance tests were used to compare subgroups, and P values , .05 were considered signifi cant. A nodule was classifi ed as benign based on confi rmed benign pathology or the absence of radiographic change as determined by the managing physician during surveillance for at least 2 years. Multivariate logistic regression was performed to identify factors associated with the use of an invasive diagnostic procedure. All statistical analyses were performed using SAS/STAT, version 9.3 (SAS Institute inc).
Results
Eighteen sites were chosen based on geographic location and ability to meet the inclusion criteria ( e- Fig 2 ) . A total of 2,579 patients were screened for eligibility. Following review, 377 patients were included in the fi nal analysis ( Fig 1 ) . Most of the exclusions were based on nodule size ( , 8 mm or . 20 mm) (n 5 1,314), missing clinical information (n 5 424), or insuffi cient follow-up time (n 5 303). Th ere was some variation at both the site level and regionally in the numbers of patients excluded because of missing data ( e-Tables 1, 2 ).
Of the 377 patients included, 283 (75%) had a nodule that was benign, and 94 (25%) had a malignant nodule ( Table 1 ) . Th e average age was 64.5 years, although patients with malignancy were slightly older ( P , .02). Th ere was an equal sex distribution. Th ose with cancer were more likely to be current or former smokers ( P , .0001). Although the number of pack-years smoked was signifi cantly higher in those with malignancy (45 vs 27, P , .0001), a substantial proportion of those with benign nodules smoked (67%). Malignant nodules were larger than benign nodules ( P , .0001), although there did not appear to be a reliable cutoff above which malignancy could be predicted. Figure 2 demonstrates the diagnostic outcome by nodule size. Twelve percent of nodules Յ 11 mm in size were malignant, whereas 40% of nodules between 16 and 20 mm were malignant.
Current smokers (OR 5 3.29; 95% CI, 1.36-7.98) and patients with larger nodules (16-20 mm) were more likely (OR 5 4.77; 95% CI, 2.95-7.72) to have a procedure (biopsy or surgery) performed. Th ere was no difference in receipt of procedure based on age, family history of cancer, or geographic location ( Table 2 ) .
To further understand nodule management decisions, we used two prediction models to determine the pCA for each individual in the study. 9 ,10 Th ese models had very good accuracy in this cohort of patients, with an area under the curve of 0.77 (95% CI, 0.72-0.81) and 0.74 (95% CI, 0.69-0.80), respectively ( e -Fig 3 ) . Because the results did not vary signifi cantly between models, we report the results from the Veteran Aff airs model here and results from the Mayo model in e- Table 3 . Table 3 lists the pretest probability for cancer by three ranges as defi ned by the CHEST guidelines for PN management: low risk (pCA , 0.05), intermediate risk (pCA 0.05 to , 0.65), and high risk ( . 0.65). 8 Th e average pCA for all patients as calculated by the model was 0.33, which is only slightly higher than the cancer prevalence of 25% in this population. Th irty-six patients had nodules that had a low risk of malignancy, and all were benign. Slightly more than one-half were followed by serial imaging alone (n 5 20, 56%). However, despite a pCA of , 0.05, 10 (28%) underwent biopsy, and six (17%) had surgical resection. Th e majority of nodules (n 5 300) fell into the intermediate-risk category, and 75% of these were benign. Forty-one patients (11%) had high-risk nodules, and 23 (58%) were benign. Th e rate of surgical resection was similar among the three groups (17%, 21%, 17%, respectively; P 5 .69). Alternative cut points for the low-risk category were investigated. All nodules with a pCA of , 0.10 were found to be benign, whereas 98% of those with a pCA of , 0.15 were benign ( Table 4 ) .
Nearly one-half of all patients (46%, n 5 175) were followed with serial imaging only. Th e median number of scans performed was three (range, one to seven). Although the majority (62%) had three to fi ve follow-up imaging studies, 4% underwent seven repeat scans. All nodules in this group were benign by resolution or 2 years of radiographic stability. Biopsy (TTNA or bronchoscopy) was performed as the most invasive procedure in 125 patients (33%) and was positive for malignancy in 44 (35%). In more than one-half (n 5 71, 57%), a specifi c benign diagnosis was obtained, whereas 10 (8%) were nondiagnostic and subsequently followed for 2 years.
A total of 77 patients (20%) had surgery as their most invasive test. Prior to surgery, 19 patients (25%) underwent a TTNA or bronchoscopy; 11 had a nondiagnostic biopsy (seven malignant, four benign at surgery), and eight had a benign biopsy result (three malignant, fi ve benign at surgery). Overall, malignancy was diagnosed in 65% (n 5 50; 95% CI, 53.2%-75.5%) of those who received surgery, whereas 35% (n 5 27; 95% CI, 24.5%-46.8%) underwent surgery for benign disease.
A PET scan was performed in 141 patients (37%). Overall, PET scan use increased with the intensity of testing (surveillance 24%, biopsy 42%, surgery 60%, P , .0001).
Results were available for 78% (n 5 110) of those who underwent PET scanning ( Fig 3 ) . Th e overall accuracy of PET scanning was 74%, with a false-positive (FP) rate of 39% and a false-negative (FN) rate of 9%. In 8-to 11-mm nodules with PET scan data (n 5 38), the FN rate was 10% and the FP rate was 36%. Nodules measuring . 11 to 15 mm (n 5 48) had FN and FP rates of 9% and 36%, respectively. The FN rate for PET scans in nodules . 15 mm (n 5 24) was 8%, and the FP rate was 55%.
In the surveillance group (n 5 175), 42 (24%) underwent PET scanning, for whom 31 reports were available. Seven (23%) had PET scan positive results and were followed with serial imaging. Among the 125 patients who underwent biopsy as the most invasive procedure, 53 (42%) underwent PET scan prior to the biopsy. Results were available in 42 cases. Twenty-nine (69%) To our knowledge, this is the first study that documents the prevalence of cancer (25%) in patients with intermediate-sized nodules who are referred to community-based pulmonologists. Th is fi nding has implications for managing PNs in the community; because the risk of cancer is substantial, patients should be managed based on their individualized risk of malignancy.
We found that a high proportion of patients who underwent surgery had benign disease without variation when stratifi ed by the pretest probability of cancer in the nodule. Th e rates of resection for benign disease varied from 9% to 23% in screening trials and surgical series. 14, 18 Guidelines recommend surgery if the pretest probability of cancer is high (pCA . 65%) because a negative biopsy result would not dissuade the physician from pursuing a defi nitive diagnosis and a positive biopsy result would lead to surgery anyway.
Th e risk models we evaluated were very good at identifying those patients who did not have cancer (100% nodules with , 5% pCA were benign), yet surgical resection was performed at rates similar to those with a high probability of cancer. Similarly, there was no diff erence in the proportion of patients undergoing surveillance when stratifi ed by pCA. Th is suggests that pulmonologists did not readily follow the guidelines because they were unaware of them, did not believe them useful, or overestimated the pCA. Th is study does not allow us to explore the reasons why pulmonologists aggressively manage some nodules that turn out to be benign. Th ere are several possible explanations as to what may have led to biopsy or surgery, and they include being misled by PET scan results, patient preferences for diagnostic certainty, an overestimation of the pCA, or incentives for procedure referral. 19 Further research is needed to determine the exact drivers of physician decision-making in PN management.
Although physicians did not appear to use pCA in making decisions about surgery or surveillance, there was a trend toward an increasing use of biopsy as the pCA increased ( P 5 .07). Th is fi nding suggests that pulmonologists may use clinical intuition and experience to distinguish benign from malignant disease, although, admittedly, data on provider years in practice and the proportion who were board certifi ed were not available. A signifi cant proportion of patients in this study with benign nodules were older and had signifi cant smoking histories and larger nodules, all which typically suggest Table 3 for expansion of abbreviations.
malignancy and may have led physicians to overestimate pCA.
In the setting of a positive or ambiguous PET scan interpretation, it is possible that the pulmonologists felt compelled to confi rm the abnormal fi ndings with a defi nitive tissue diagnosis. Th e FP rate for PET scans in this study was 39%, as compared with the 5% to 28% rate [20] [21] [22] [23] [24] [25] [26] reported in the literature. Conversely, in some instances, PET scan results did not seem to be taken into account when making management decisions. For instance, in the surveillance-only group, eight patients with positive PET scans did not undergo further diagnostic procedures. Similarly, in the biopsy group, 13 patients with negative PET scan results still underwent an invasive procedure. Another consideration is that patient preferences infl uenced the decision toward more aggressive care. Th e guidelines advocate a patient-centered approach to decision-making aft er patients are informed of the pCA. 8 Th us, some patients may request surgery despite a low pCA because of anxiety about the unknown and an unwillingness to continue with surveillance. 27 Th e cornerstone of management for PNs has been calculating pCA and acting on those calculations. 8 Th is study provides evidence that physicians may not use pCA to guide decision-making and also suggests that an alternative low-risk-category pCA higher than the current CHEST guidelines would shift more patients into the surveillance management strategy without missing malignancy.
Although the exact reason for management decisions cannot be elicited, it is clear that there is wide variation in the management of PNs by pulmonologists. Th e goal for nodule management is to effi ciently detect lung cancer while decreasing the number of unnecessary invasive procedures. A number of radiographic improvements, novel tests, and biomarkers have been developed with the potential to help determine the likelihood of malignancy in a nodule. Th e use of semiautomated volumetric soft ware to measure the diameter and volume doubling time of a nodule between scans has been used successfully in screening trials to improve the sensitivity, specifi city, and negative predictive value of CT scans. 28 Similarly, volumetric measurements added to traditional nodule malignancy prediction models have also been shown to improve the classifi cation of malignancy from 60% to 80%, with better performance than that of the traditional model. 29 Identifi cation of aberrations in airway epithelial cell gene expression, circulating tumor antibodies, plasma proteomics, exhaled breath analysis, and microRNA are all being studied actively for use in diagnosing lung cancer. [30] [31] [32] [33] [34] [35] Th ese novel tests have the potential to further refi ne nodule management and alleviate the ambiguity of current management strategies.
Th is study has several limitations. First, the retrospective design precluded a complete understanding of the rationale for test ordering. However this design did allow for a defi nitive fi nal diagnosis to be established with biopsy, surgery, or 2 years of radiographic surveillance. Second, incomplete PET scan data coupled with difficulties in scan interpretation resulted in variations in the defi nition of a "positive" PET scan. To overcome this limitation, we developed a hierarchical algorithm for determining a defi nitive PET scan result. Finally, excluding patients who had had a CT scan . 60 days prior to initial consultation may have selectively excluded some patients with low probability nodules.
Th is study also has several strengths. Th e fi ndings are generalizable because of the large sample size, geographic distribution, and multicenter design. Th e study also focuses on a size range of nodules (8-20 mm) that most oft en presents a diagnostic dilemma for physicians. 16 Nodules smaller than 8 mm are followed with surveillance because the pCA is low, PET scans do not reliably characterize small nodules, and biopsy of small nodules is diffi cult; by contrast, nodules . 20 mm are likely to undergo biopsy or surgery because the pCA is high. As opposed to other published series, this study allowed for all three management strategies to be studied in detail.
Conclusions
In conclusion, one in four patients referred with a nodule to a community pulmonologist has cancer, making management decisions critical to patient outcomes. To spare patients unnecessary testing, use of a higher pCA to defi ne a nodule as low risk seems reasonable. Th ere is a wide variation in how nodules are managed and the choice of management may be infl uenced by a variety of factors in addition to pretest probability. Future research should focus on what infl uences decision-making in PN management so that interventions may be developed to promote proper guideline adherence and avoidance of unnecessary invasive procedures. of the manuscript, for the integrity of the data, and the accuracy of the data analysis, including and especially any adverse eff ects. N. T. T., J. A., and G. A. S. contributed to the data analysis and interpretation, writing of the manuscript, and components of the study design; M. K. G. contributed to the data interpretation and writing of the manuscript; P. K. contributed to the study design and editing of the manuscript; G. D. and A. V. contributed to the data interpretation and editing of the manuscript ; and K. C. F. contributed to the study design, data analysis and interpretation, and writing of the manuscript. 
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